Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) just unveiled an update.
Charmacy Pharmaceutical Co., Ltd. has announced that its board of directors will hold a meeting on March 28, 2025, to consider and approve the company’s annual results for the year ended December 31, 2024. The meeting will also discuss the recommendation for the payment of a final dividend, if applicable. This announcement signifies a critical step in the company’s financial reporting and potential dividend distribution, which could impact investor sentiment and the company’s market positioning.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a joint stock limited liability company incorporated in the People’s Republic of China. It operates within the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products.
YTD Price Performance: -20.61%
Average Trading Volume: 4,805
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$840.2M
See more insights into 2289 stock on TipRanks’ Stock Analysis page.